Clinical Evaluation of Verapamil in Angina Pectoris

Overview

Journal Br Med J

Specialty General Medicine

Date 1968 Jul 27

PMID 4969551

Citations 31

Authors

G Sandler

G A Clayton

S G Thornicroft

Affiliations

Soon will be listed here.

Abstract

A controlled double-blind study of verapamil in 16 anginal patients used two dose levels-40 mg. t.d.s. and 120 mg. t.d.s.-and was compared with propranolol 100 mg. t.d.s. At the higher dosage verapamil produced a significant improvement in frequency of angina, trinitrin consumption, and exercise tolerance, and had a favourable and significant effect on the amount and duration of ischaemic S-T depression occurring in the electrocardiogram during exercise. In the lower dose verapamil produced significant subjective improvement but no objective benefit in the electrocardiogram. No significant differences were found between the favourable results with the higher dosage of verapamil and propranolol.The action of verapamil is not fully understood, but its favourable effects in angina may be due to a direct action on the myocardium, possibly with accompanying coronary vasodilatation.

Citing Articles

TXNIP/TBP-2: A Master Regulator for Glucose Homeostasis.

Yoshihara E Antioxidants (Basel). 2020; 9(8).

PMID: 32824669 PMC: 7464905. DOI: 10.3390/antiox9080765.

Discovery and Development of Calcium Channel Blockers.

Godfraind T Front Pharmacol. 2017; 8:286.

PMID: 28611661 PMC: 5447095. DOI: 10.3389/fphar.2017.00286.

Stereoselective Inhibition of the hERG1 Potassium Channel.

Grilo L, Carrupt P, Abriel H Front Pharmacol. 2011; 1:137.

PMID: 21833176 PMC: 3153011. DOI: 10.3389/fphar.2010.00137.

Calcium antagonists: A new class of therapeutic agents.

Gunawan A, Massumi A, Hall R Cardiovasc Dis. 1981; 8(3):413-420.

PMID: 15216199 PMC: 287966.

Differential effects of the calcium antagonist, verapamil, on lumen sizes of terminal arterioles and muscular venules in the rat mesenteric, pial and skeletal muscle microvasculatures.

Altura B, Altura B, Gebrewold A Br J Pharmacol. 1980; 70(3):351-3.

PMID: 7437647 PMC: 2044357. DOI: 10.1111/j.1476-5381.1980.tb08709.x.

References

LUEBS E, Cohen A, ZALESKI E, BING R . Effect of nitroglycerin, intensain, isoptin and papaverine on coronary blood flow in man. Measured by the coincidence counting technic and rubidium. Am J Cardiol. 1966; 17(4):535-41. DOI: 10.1016/0002-9149(66)90245-1. View

Neumann M, LUISADA A . Double blind evaluation of orally administered iproveratril in patients with angina pectoris. Am J Med Sci. 1966; 251(5):552-6. DOI: 10.1097/00000441-196605000-00008. View

Birkett D, Chamberlain D . Beta-adrenergic blockade in angina pectoris: a method of treadmill assessment. Br Med J. 1966; 2(5512):500-2. PMC: 1943583. DOI: 10.1136/bmj.2.5512.500. View

Hamer J, Sowton E . Effects of propranolol on exercise tolerance in angina pectoris. Am J Cardiol. 1966; 18(3):354-60. DOI: 10.1016/0002-9149(66)90053-1. View

GRANT R, KEELAN P, KERNOHAN R, Leonard J, NANCEKIEVILL L, Sinclair K . Multicenter trial of propranolol in angina pectoris. Am J Cardiol. 1966; 18(3):361-5. DOI: 10.1016/0002-9149(66)90054-3. View

MIGNAULT J . Coronary cineangiographic study of intravenously administered isoptin. Can Med Assoc J. 1966; 95(24):1252-3. PMC: 1935727. View

BAILAR 3rd J . Thromboembolism and oestrogen therapy. Lancet. 1967; 2(7515):560. DOI: 10.1016/s0140-6736(67)90529-6. View

Sandler G . Comparison of radiocardiography and conventional electrocardiography in the exercise tolerance test. Br Heart J. 1967; 29(5):719-24. PMC: 459182. DOI: 10.1136/hrt.29.5.719. View

FRIEDEN J . Propranolol in the treatment of angina pectoris. Am Heart J. 1967; 74(3):431-3. DOI: 10.1016/0002-8703(67)90085-3. View

10.

GRANT R, McDeritt D, Shanks R . Is verapamil a beta-blocker?. Lancet. 1968; 1(7538):362-3. DOI: 10.1016/s0140-6736(68)90829-5. View

11.

Frohlich E, TARAZI R, DUSTAN H, PAGE I . The paradox of beta-adrenergic blockade in hypertension. Circulation. 1968; 37(3):417-23. DOI: 10.1161/01.cir.37.3.417. View

12.

HOFBAUER K . [On the therapy of stenocardiac complaints with Iproveratril]. Wien Med Wochenschr. 1966; 116(52):1155-6. View

13.

KNOCH G, Schlepper M, WITZLEB E . [Isoptin studies on normal subjects and patients with coronary disease]. Med Klin. 1963; 58(36):1485-9. View

14.

RUSSEK H, ZOHMAN B, DORSET V . Objective evaluation of coronary vasodilator drugs. Am J Med Sci. 1955; 229(1):46-54. DOI: 10.1097/00000441-195501000-00008. View

15.

Cole S, Kaye H, GRIFFITH G . Assay of antianginal agents; the rapport period. J Am Med Assoc. 1958; 168(3):275-7. DOI: 10.1001/jama.1958.63000030006011b. View

16.

LLOYD-THOMAS H . The exercise electrocardiogram in patients with cardiac pain. Br Heart J. 1961; 23:561-77. PMC: 1017829. DOI: 10.1136/hrt.23.5.561. View

17.

Bellet S, Eliakim M, DELIYIANNIS S, Lavan D . Radioelectrocardiography during exercise in patients with angina pectoris. Comparison with the postexercise electrocardiogram. Circulation. 1962; 25:5-14. DOI: 10.1161/01.cir.25.1.5. View

18.

DORNHORST A, Robinson B . Clinical pharmacology of a beta-adrenergic-blocking agent (Nethalide). Lancet. 1962; 2(7251):314-6. DOI: 10.1016/s0140-6736(62)90104-6. View

19.

Prichard B, Dickinson C, ALLEYNE G, Hurst P, Hill I, ROSENHEIM M . EFFECT OF PRONETHALOL IN ANGINA PECTORIS. Br Med J. 1963; 2(5367):1226-9. PMC: 1873319. DOI: 10.1136/bmj.2.5367.1226. View

20.

MELVILLE K, SHISTER H, Huq S . IPROVERATRIL: EXPERIMENTAL DATA ON CORONARY DILATATION AND ANTIARRHYTHMIC ACTION. Can Med Assoc J. 1964; 90:761-70. PMC: 1922556. View